The BexBody™ platform technology is a unique technology of PnP Biopharm that applies the BexPress™ platform technology to the VHH single-domain antibody derived from camelid animals, and can easily be expanded to pharmaceuticals and diagnostic kits in various ways.
Existing traditional antibodies (IgG-type mAbs) are large (about 150 kDa) and have a complicated molecular structure consisting of two-chains (H+L), causing high cost and low efficiency in production, and also low tissue penetration. The VHH single-domain antibody is an antibody composed of a variable region that binds to an antigen from a heavy chain-only antibody that exists in camelids. Due to its small size and high production efficiency, it is superior to the traditional antibodies in many applications.
The BexBody™ platform technology is a proprietary technology that combines the existing VHH single-domain antibody and the BexPress™ platform technology. BexBodies derived have desirable properties such as high productivity, affinity, stability, and tissue penetration. In addition, it can be used in a wide range of fields by combining various types of antibodies to form double or triple antibodies.
Due to its small size and simple structure, it is possible to develop antibody variants in various formats, such as bispecific BexBody™, BexBody™ drug conjugate (BDC), and BexBody™ CAR-T. It has a high tissue penetration property and is rapidly eliminated through the kidneys, making it possible to develop molecular imaging agents or theranostic antibody drugs that are accompanied by treatment and diagnosis. In addition, it is possible to develop an in vitro diagnostic kit with improved sensitivity by maximizing the integration rate per unit area, or to develop a delivery system of CNS disease treatment drugs through a BexBody™ crossing blood-brain barrier (BBB), or to develop drugs with improved serum half-life using serum albumin-binding BexBody™.